Author, as appears in the article.: Martin-Loeches I, Bisanti A, Diaz E, Rodriguez A

Department: Medicina i Cirurgia

URV's Author/s: Rodríguez Oviedo, Alejandro Hugo

Keywords: Vat Vap Urinary-tract-infections Sepsis Safety Resistance Renal-function Pseudomonas-aeruginosa Population pharmacokinetics Pneumonia Plus metronidazole P. aeruginosa P Multicenter Double-blind Cephalosporin Aeruginosa

Abstract: © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Patients admitted to hospitals are at risk of developing nosocomial infections. These types of infections typically occur in immune compromised patients. Furthermore, nosocomial infections are frequently caused by resistant organisms, including nonfermenting gram-negative bacilli such as Pseudomonas aeruginosa. Areas covered: P. aeruginosa is a hazardous pathogen. It can resist numerous antibiotics, due to several resistance mechanisms. It is associated with serious illnesses, particularly hospital acquired infections including ventilator associated pneumonia. In the past, only a limited number of anti-pseudomonal drugs were available. However, several therapeutic advancements have been made, in recent years, to target P. aeruginosa, including the development of the new cephalosporin: ceftolozane-tazobactam. Expert opinion: Ceftolozane-tazobactam is a combination of a novel semi-synthetic fifth generation cephalosporin with a well-established beta-lactamase inhibitor. From a structural perspective, ceftolozane-tazobactam has attested increased stability to AmpC β-lactamases. Additionally, ceftolozane-tazobactam is less affected by changes in efflux pumps and porin permeability due to an enhanced affinity to certain penicillin-binding proteins (PBPs). This enables the molecule to overcome the most common anti-drug resistant mechanisms of bacteria. According to previous clinical trials conducted, ceftolozane-tazobactam must be considered when treating patients with confirmed or suspected P. aeruginosa respiratory tract infections, either nosocomial pneumonia or ventilator-associated pneumonia.

Thematic Areas: Virology Saúde coletiva Química Pharmacology & pharmacy Microbiology (medical) Microbiology Medicina ii Medicina i Infectious diseases Farmacia Engenharias iv Enfermagem Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Biotecnología Biodiversidade

licence for use: https://creativecommons.org/licenses/by/3.0/es/

ISSN: 14787210

Author's mail: alejandrohugo.rodriguez@urv.cat

Author identifier: 0000-0001-8828-5984

Record's date: 2023-09-02

Papper version: info:eu-repo/semantics/acceptedVersion

Link to the original source: https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1794816?needAccess=true

Licence document URL: http://repositori.urv.cat/ca/proteccio-de-dades/

Papper original source: Expert Review Of Anti-Infective Therapy. 18 (12): 1-9

APA: Martin-Loeches I, Bisanti A, Diaz E, Rodriguez A (2020). Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia. Expert Review Of Anti-Infective Therapy, 18(12), 1-9. DOI: 10.1080/14787210.2020.1794816

Article's DOI: 10.1080/14787210.2020.1794816

Entity: Universitat Rovira i Virgili

Journal publication year: 2020

Publication Type: Journal Publications